{
     "PMID": "10781012",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20000627",
     "LR": "20140615",
     "IS": "0007-1188 (Print) 0007-1188 (Linking)",
     "VI": "130",
     "IP": "1",
     "DP": "2000 May",
     "TI": "Role of uptake inhibition and autoreceptor activation in the control of 5-HT release in the frontal cortex and dorsal hippocampus of the rat.",
     "PG": "160-6",
     "AB": "1. Using brain microdialysis, we compared the relative role of 5-hydroxytryptamine (5-HT; serotonin) blockade and somatodendritic 5-HT(1A) and/or terminal 5-HT(1B) autoreceptor activation in the control of 5-HT output. 2. Fluoxetine (10 mg kg(-1) i.p.) doubled the 5-HT output in frontal cortex and dorsal hippocampus. The 5-HT(1A) receptor antagonist WAY 100635, (0.3 mg kg(-1) s.c.) potentiated the effect of fluoxetine only in frontal cortex (to approximately 500 % of baseline). 3. Methiothepin (10 mg kg(-1) s.c.) further enhanced the 5-HT rise induced by fluoxetine+WAY 100635, to 835+/-179% in frontal cortex and 456+/-24% in dorsal hippocampus. Locally applied, methiothepin potentiated the fluoxetine-induced 5-HT rise more in the former area. 4. The selective 5-HT(1B) receptor antagonist SB-224289 (4 mg kg(-1) i.p.) enhanced the effect of fluoxetine (10 mg kg(-1) i.p.) in both areas. As with methiothepin, SB-224289 (4 mg kg(-1) i.p.) further enhanced the 5-HT increase produced by fluoxetine+WAY 100635 more in frontal cortex (613+/-134%) than in dorsal hippocampus (353+/-59%). 5. Locally applied, fluoxetine (10 - 300 microM; EC(50)=28 - 29 microM) and citalopram (1 - 30 microM; EC(50)=1.0 - 1.4 microM) increased the 5-HT output two to three times more in frontal cortex than in dorsal hippocampus. These data suggest that the comparable 5-HT increase produced by systemic fluoxetine in frontal cortex and dorsal hippocampus results from a greater effect of reuptake blockade in frontal cortex that is offset by a greater autoreceptor-mediated inhibition of 5-HT release. As a result, 5-HT autoreceptor antagonists preferentially potentiate the effect of fluoxetine in frontal cortex.",
     "FAU": [
          "Hervas, I",
          "Queiroz, C M",
          "Adell, A",
          "Artigas, F"
     ],
     "AU": [
          "Hervas I",
          "Queiroz CM",
          "Adell A",
          "Artigas F"
     ],
     "AD": "Department of Neurochemistry, Institut d'Investigacions Biomediques de Barcelona, Spain.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "PL": "England",
     "TA": "Br J Pharmacol",
     "JT": "British journal of pharmacology",
     "JID": "7502536",
     "RN": [
          "0 (Autoreceptors)",
          "0 (Receptor, Serotonin, 5-HT1B)",
          "0 (Receptors, Serotonin)",
          "0 (Receptors, Serotonin, 5-HT1)",
          "0 (Serotonin Uptake Inhibitors)",
          "01K63SUP8D (Fluoxetine)",
          "333DO1RDJY (Serotonin)"
     ],
     "SB": "IM",
     "MH": [
          "Animals",
          "Autoreceptors/*drug effects/metabolism",
          "Fluoxetine/*pharmacology",
          "Frontal Lobe/*drug effects/metabolism",
          "Hippocampus/*drug effects/metabolism",
          "Male",
          "Rats",
          "Rats, Wistar",
          "Receptor, Serotonin, 5-HT1B",
          "Receptors, Serotonin/*drug effects/metabolism",
          "Receptors, Serotonin, 5-HT1",
          "Serotonin/*metabolism",
          "Serotonin Uptake Inhibitors/*pharmacology"
     ],
     "PMC": "PMC1572046",
     "EDAT": "2000/04/26 09:00",
     "MHDA": "2000/07/06 11:00",
     "CRDT": [
          "2000/04/26 09:00"
     ],
     "PHST": [
          "2000/04/26 09:00 [pubmed]",
          "2000/07/06 11:00 [medline]",
          "2000/04/26 09:00 [entrez]"
     ],
     "AID": [
          "10.1038/sj.bjp.0703297 [doi]"
     ],
     "PST": "ppublish",
     "SO": "Br J Pharmacol. 2000 May;130(1):160-6. doi: 10.1038/sj.bjp.0703297.",
     "term": "hippocampus"
}